← All trials
NCT05244798
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- Feb 17, 2022
- Last posted
- Oct 25, 2022
- Enrollment
- 420
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Electronic Science and Technology of ChinaLead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Collaborator
- Hebei UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Peking UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Anyang Regional HospitalCollaborator
- Shantou UniversityCollaborator
- University of Electronic Science and Technology of ChinaReponsible party - principal investigator
- GeneCast Biotechnology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.